Drugs / human retinal progenitor cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02320812 | Jun 2015 → Jul 2017 | retinitis pigmentosa | jCyte, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04604899 | Dec 2020 → Mar 2022 | retinitis pigmentosa | jCyte, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03073733 | Mar 2017 → Nov 2020 | retinitis pigmentosa | jCyte, Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | jCyte, Inc | Results jCyte Announces Publication of Phase I/IIa Safety Study of Retinal Progenitor Cells in Retinitis Pigmentosa in Frontiers in Cellular Neuroscience jcyte.com ↗
Intravitreal RPC injection was well tolerated at all dose levels. |
| 2024-02-21 | jCyte, Inc | Regulatory jCyte Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in The Second Half of 2024 jcyte.com ↗
John Sholar, Chief Executive Officer of jCyte, expressed satisfaction with FDA’s review of the planned phase 2/3 clinical trial design including FDA’s approval of the primary endpoint and the two jCell doses to be included in the study. |
| 2021-11-15 | jCyte, Inc | Results jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy jcyte.com ↗
Dr. Kuppermann explained how jCell upregulates and restores the function of cone photoreceptors, and the mechanism by which this is achieved. |
| 2021-05-03 | jCyte, Inc | Results jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy jcyte.com ↗
had an early, sustained, and significant mean improvement in the primary endpoint of best corrected visual acuity (BCVA) (+16.27 letters vs. Sham +1.85 letters between baseline and the final 12 month study visit, p=0.003). |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human retinal progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04604899 ↗ |
| Known as | hRPC | “single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)” NCT02320812 ↗1“single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)” NCT04604899 ↗ |
| Modality | Cell therapy | “Human allogeneic retinal progenitor cells will be injected into adults with advanced RP” NCT02320812 ↗ |
| Route | Intravitreal | “each receiving a single intravitreal injection of one of: 0.5, 1.0, 2.0, or 3.0 × 106 allogeneic RPCs.” PMID 40927136 ↗ Aug 2025 |